A breast implant maker's stock could climb as GLP-1 market booms, TD Securities says
Establishment Labs is poised to get a boost from widening GLP-1 use as it is set to expand its breast implant business in the U.S., per TD Securities.
TL;DR
- TD Securities believes the proliferation of GLP-1 drugs is increasing demand for breast augmentation procedures, benefiting Establishment Labs.
- The bank has a buy rating and a $117 price target on Establishment Labs shares, indicating potential for significant upside.
- GLP-1 use has risen, with approximately one in eight adults reportedly taking such drugs in 2025.
- U.S. cosmetic surgery market growth accelerated, with breast augmentation volumes increasing notably.
- Cosmetic procedures linked to post-weight loss patients saw significant growth, suggesting a positive trend for Establishment Labs' offerings.
- Establishment Labs' Preservé line is expected to further expand the market upon its broader U.S. launch.
- All nine analysts covering Establishment Labs have a buy or strong buy rating on the stock.